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Effect of a Detailed Family History of Melanoma on
Risk for Other Tumors: A Cohort Study Based on the
Nationwide Swedish Family-Cancer Database
Tianhui Chen1,4, Mahdi Fallah1,4, Elham Kharazmi1, Jianguang Ji2, Kristina Sundquist2,3 and Kari Hemminki1,2
Using the Swedish Family-Cancer Database, we assessed the effect of a detailed family history of melanoma on
risk for other tumors (other than melanoma). Among 248,011 individuals with a family history of melanoma, 43,931
other tumors were diagnosed from 1958 to 2010. Standardized incidence ratios (SIRs) were calculated for other
tumors in patients who had a family history of melanoma, as compared with those without. A detailed family
history of melanoma was investigated according to an increasing number of melanomas in either 1 or X2 first-
degree relatives (FDRs). Associations were considered significant when there were at least two independently
significant SIRs or a statistically significant trend of increasing SIRs with increasing number of melanomas in
relatives. The applied criteria for significant associations were convincingly met by pancreatic, breast, prostate,
and squamous cell skin tumors and ependymoma, although there was significant but not overwhelming
evidence for thyroid, parathyroid, lung, and unknown primary tumors, meningioma, mycosis fungoides, and
myeloid leukemia. To our knowledge, no studies have previously considered a detailed family history of
melanoma and the use of internal validation to assess familial associations of melanoma with other tumors. We
established associations for 12 other tumors, and the associations for myeloid leukemia, parathyroid, and
unknown primary tumors are, to our knowledge, previously unreported.
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INTRODUCTION
Familial melanoma refers to the clustering of melanomas among
X2 first-degree relatives (FDRs) (Goldstein and Tucker, 2001). In
Sweden, about 5% of melanoma patients have a family history of
melanoma (Hemminki et al., 2008). In melanoma families, many
patients present with multiple melanomas, which is also the
feature in the Familial Atypical Multiple Mole Melanoma
(FAMMM) syndrome (also known as dysplastic nevus syndrome
or familial melanoma syndrome; Czajkowski et al., 2004; Lynch
et al., 2008). The FAMMM syndrome is caused by mutations in
the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene on
chromosome 9p21 (Rulyak et al., 2003). These mutations also
predispose patients to pancreatic cancer (Lynch et al., 2008).
It has been reported that some other cancers also cluster in
melanoma families, including esophageal, colorectal, breast,
prostate, kidney, squamous cell skin, nervous system, and
connective tissue cancers, multiple myeloma, and leukemia
(Amundadottir et al., 2004; Larson et al., 2007; Brandt et al.,
2011; Hemminki et al., 2012). It is possible that other genes
and shared environmental factors (e.g,, sun exposure) explain
the reported clustering. However, if such clustering was due to
shared genetic or environmental causes, one could assume that
these constitute familial clustering of melanoma and associated
cancers. Thus, the associations between melanoma and other
cancers should be stronger if familial cases are to be
compared. None of the above studies considered a detailed
family history of melanoma (multiple melanomas in a single
affected relative or multiple affected relatives).
In the present study, we used the largest database on familial
cancer in the world, the nationwide Swedish Family-Cancer
Database (FCD), to assess discordant familial associations of
melanoma with other tumors by considering a detailed family
history of melanoma (the effect of a detailed family history of
melanoma on risk for other tumors). We provide a compre-
hensive analysis on the familial clustering of multiple melano-
mas with other tumors, and show a number of, to our
knowledge, previously unreported associations. As these types
of studies have an inherent problem of multiple comparisons,
we seek internal validation for any putative finding.
RESULTS
The risk for other tumors in patients with a detailed family
history of melanoma ((1, 2, 3, and X4) melanomas in 1 FDR
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or X2 FDRs) is presented in Table 1. Our analysis revealed a
clear and statistically significant trend of increasing standar-
dized incidence ratios (SIRs) with an increasing number of
melanomas in one FDR for pancreatic, breast, and squamous
cell skin tumors, although lung tumors had a borderline
significant trend of increasing SIRs (P-trend¼ 0.05). In addi-
tion, there were two independently significant SIRs in one
FDR for both unknown primary tumor and ependymoma.
However, for lung and unknown primary tumors, the SIRs
were borderline significant and were very weak (p1.3). In
Table 1, only one significant SIR (X1.5) was observed for
some tumors, including mycosis fungoides, bone (explained
by osteosarcoma), eye, and ovarian tumors. For endocrine
tumors, the increase was noted for parathyroid and pituitary
tumors, whereas among leukemias the increase was noted for
myeloid leukemia.
Sex-specific risk for other tumors is presented in Table 2 for
men and in Table 3 for women, but sex-specific tumors from
Table 1 are not repeated in Tables 2 and –3. For men, a
statistically significant trend of increasing SIRs with an increas-
ing number of melanomas in one FDR was found for squamous
cell skin tumor. In addition, for mycosis fungoides, there were
two independently significant SIRs (in 1 FDR orX2 FDRs), but
the SIRs were borderline significant and the number of cases
was very small. In Table 2, only one significant SIR (X1.5) was
observed for endocrine tumor. Significant associations for
pancreatic and lung tumors were observed only for women
(Table 3), although the SIRs for pancreatic and lung tumors in
men tended to exceed 1.0 but did not reach statistical
significance (Table 2). In addition, for women (Table 3) there
were two independently significant SIRs for meningioma and
four SIRs for leukemia (explained by myeloid leukemia as there
were two independently significant SIRs for myeloid leukemia
but not for other subsites), although the SIRs for meningioma
and leukemia in men also tended to exceed 1.0 but did not
reach statistical significance. In Table 3, only one significant
SIR (X1.5) was observed in women for endocrine (explained
by parathyroid tumor) and bone tumors (explained by osteo-
sarcoma). In addition, the SIR for thyroid tumor in men and
women showed a small excess of 1.3 and 1.2, respectively.
DISCUSSION
On the basis of overall and sex-specific analyses, the applied
criteria for a significant familial association of melanoma with
a discordant other tumor (defined as having at least two
independently significant SIRs) were convincingly met by five
tumors, including pancreatic, breast, prostate, and squamous
cell skin tumors and ependymoma. The criteria were also met
by seven tumors, including thyroid, parathyroid, lung, and
unknown primary tumors, meningioma, mycosis fungoides,
and myeloid leukemia, but the evidence was not overwhelm-
ing because of the borderline significance of SIRs or the small
number of cases. Irrespective of whether or not we used the
additional criteria of the trend test, the significant associations
identified by having at least two independently significant SIRs
did not change.
Our study had several strengths. First, we used internal
validation to reduce chance findings (Amundadottir et al.,
2004; Larson et al., 2007; Brandt et al., 2011). Second, no
studies have previously used a detailed family history of
melanoma (increasing number of melanomas in 1 FDR or
X2 FDRs) to assess familial associations of melanoma with
other tumors. Third, the present study had the largest ever
sample size for a family history of melanoma (248,011) and
data on all tumors and family relationships were retrieved
from registered sources of high quality. Fourth, detailed
analyses on the associations of melanoma with subsites of
nervous system and endocrine tumors, leukemia, and with the
histological subtypes of nervous system tumors were
previously unreported. The major limitation of the study
concerns multiple testing, as these types of studies have an
inherent problem of multiple comparisons. However, we used
internal validation to reduce chance findings by considering
an association ‘‘significant’’ only when there were at least two
independently significant SIRs, or a statistically significant
trend of increasing SIRs with an increasing number of
melanomas in 1 FDR or X2 FDRs. Therefore, the
established familial associations of melanoma with 12 other
tumors in our study were much less prone to chance findings.
The associations for prostate, breast, and squamous cell skin
tumors and leukemia are consistent with the analyses from the
earlier versions of the Swedish FCD (Brandt et al., 2011;
Hemminki et al., 2012) and with the data from USA (Larson
et al., 2007) and Iceland (Amundadottir et al., 2004).
Furthermore, our findings are consistent with previous
studies on the association of melanoma with pancreatic,
thyroid, and lung cancers (Lynch et al., 1981, 1983; Puig
et al., 1997; Borg et al., 2000; Hemminki et al., 2001b) and
with case reports on the association for ependymoma,
meningioma, and mycosis fungoides (Azizi et al., 1995;
Pielop et al., 2003; Evans et al., 2004). To our knowledge,
associations of melanoma with myeloid leukemia,
parathyroid, and unknown primary tumors have not been
previously reported.
It is plausible that shared susceptibility genes are involved in
some of the observed associations. CDKN2A mutations may
contribute to the associations for pancreatic cancer as they
cause the FAMMM syndrome (Rulyak et al., 2003) and also
predispose the patient to pancreatic cancer (Lynch et al.,
2008). As the FAMMM syndrome has also been reported to
include lung and breast cancers (Lynch et al., 1981, 1983;
Puig et al., 1997), it may partly explain the associations with
these tumors. Additional contributions to the cluster of
melanoma with pancreatic, breast, and prostate tumors may
be mediated by BRCA2 mutations (Ford et al., 1998; Breast
Cancer Linkage Consortium, 1999; Liede et al., 2004). The
mutation (L374F) of the SLC45A2 (MATP) gene, associated
with squamous cell skin tumor and melanoma (Stacey et al.,
2009), may contribute to the cluster of melanoma with
squamous cell skin tumor. As the PTEN-hamartoma
syndrome, with germline PTEN mutations, features elevated
risks for melanoma and for breast, thyroid, and endometrial
cancers (Bubien et al., 2013), it may contribute to the
observed associations for breast and thyroid tumors. The
associations of melanoma with meningioma and lung tumor
may also be in part due to germline mutations in the recently
T Chen et al.
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described BAP1 gene (Wiesner et al., 2012). To our
knowledge, no susceptibility gene has been described for
the five tumors associated with melanoma (out of the total 12
tumors with observed associations), including ependymoma,
mycosis fungoides, myeloid leukemia, parathyroid, and
unknown primary tumors.
In addition to shared genetic factors, shared environmental
effects (sun exposure shared by family members) may influ-
ence some of the observed associations. Solar UVR damages
DNA and initiates the development of all types of skin tumors
(Goldstein and Tucker, 2001; Narayanan et al., 2010; Mason
and Reichrath, 2013). UVR-induced immunosuppression
(Cooper et al., 1992; Ullrich, 2005) has also been
implicated in the origin of squamous cell skin cancer
and melanoma (Ullrich, 2005). Similarly, UVR-induced
immunosuppression may contribute to the observed associa-
tions for myeloid leukemia and mycosis fungoides, as
supported by other studies (Pielop et al., 2003; Gale and
Opelz, 2012). However, surveillance bias may contribute to
the association of melanoma with mycosis fungoides, because
benign skin lesions would be observed in dermatological
checkups (Bermejo and Hemminki, 2005; Shah et al., 2007).
In addition, surveillance bias may contribute to the observed
associations for many benign tumors, as relatives of melanoma
patients may participate in screening more frequently
compared with others (Bermejo and Hemminki, 2005; Shah
et al., 2007).
In conclusion, we found convincing discordant familial
associations for five tumors, including pancreatic, breast,
prostate, and squamous cell skin tumors and ependymoma.
There was significant but not overwhelming evidence on the
associations for seven tumors, including thyroid, parathyroid,
lung, and unknown primary tumors, meningioma, mycosis
fungoides, and myeloid leukemia. To our knowledge, no
Table 2. Standardized incidence ratios (SIRs) of other tumors in male patients with other tumors with a detailed
family history of melanoma in Sweden, 1958–20101
Number of melanomas in one FDR Single melanoma
1 2 3 X4 in X2 FDRs
Tumor sites N SIR 95% CI N SIR 95% CI N SIR 95% CI N SIR 95% CI P-trend N SIR 95% CI
Pancreas 345 0.9 (0.8–1.0) 20 1.0 (0.6–1.6) 5 1.9 (0.6–4.3) 2 2.5 (0.3–8.9) 0.24 14 1.4 (0.7–2.3)
Lung 1,270 0.9 (0.9–1.0) 78 1.1 (0.9–1.4) 9 1.0 (0.4–1.9) 3 1.0 (0.2–2.9) 0.30 42 1.2 (0.8–1.6)
Skin (squamous cell) 1,749 1.4 (1.3–1.4) 104 1.7 (1.4–2.1) 23 2.9 (1.8–4.3) 5 2.0 (0.6–4.6) 0.04 68 2.0 (1.6–2.6)
Eye 50 0.9 (0.7–1.2) 5 2.0 (0.6–4.6) 0 0 0.31 3 2.1 (0.4–6.2)
Nervous system 587 1.1 (1.0–1.2) 30 1.2 (0.8–1.7) 7 2.0 (0.8–4.1) 1 0.9 (0.0–4.8) 0.48 12 0.8 (0.4–1.5)
Glioma 279 1.1 (0.9–1.2) 18 1.4 (0.8–2.2) 5 2.8 (0.9–6.6) 1 1.7 (0.0–9.3) 0.23 8 1.1 (0.5–2.1)
Ependymoma 23 1.4 (0.9–2.1) 3 3.7 (0.8–10.9) 0 0 0.44 0
Meningioma 104 1.1 (0.9–1.4) 3 0.7 (0.1–2.0) 1 1.6 (0.0–9.2) 0 0.79 1 0.4 (0.0–2.2)
Thyroid glands 108 1.3 (1.1–1.5) 6 1.5 (0.5–3.2) 1 1.7 (0.0–9.4) 1 7.3 (0.2–40.6) 0.55 2 0.9 (0.1–3.1)
Endocrine glands 205 1.1 (1.0–1.3) 13 1.5 (0.8–2.6) 0 0 0.79 15 3.0 (1.7–4.9)
Parathyroid glands 84 1.1 (0.9–1.4) 4 1.1 (0.3–2.8) 0 0 0.70 5 2.4 (0.8–5.5)
Pituitary glands 68 1.1 (0.9–1.4) 3 1.1 (0.2–3.1) 0 0 0.66 5 2.9 (1.0–6.9)
Bone 54 1.1 (0.8–1.4) 5 2.0 (0.7–4.7) 1 2.9 (0.1–16.0) 0 0.38 1 0.7 (0.0–4.1)
Osteosarcoma 12 0.9 (0.5–1.6) 1 1.5 (0.0–8.5) 0 0 0.76 0 (0.5–1.6)
Connective tissue 146 1.2 (1.0–1.4) 6 1.0 (0.4–2.2) 0 0 0.76 1 0.3 (0.0–1.7)
Non-Hodgkin lymphoma 549 1.0 (0.9–1.1) 23 0.9 (0.6–1.3) 6 1.7 (0.6–3.6) 4 3.5 (0.9–8.9) 0.75 21 1.4 (0.9–2.1)
Mycosis fungoides 15 1.4 (0.8–2.4) 0 0 1 42.9 (1.1–238.9) NC 3 10.5 (2.2–30.5)
Leukemia 585 1.0 (0.9–1.1) 23 0.8 (0.5–1.3) 4 1.1 (0.3–2.7) 2 1.7 (0.2–6.1) 0.83 20 1.3 (0.8–2.1)
Myeloid leukemia 190 0.9 (0.8–1.1) 9 0.9 (0.4–1.7) 2 1.5 (0.2–5.4) 2 2.5 (0.6–16.9) 0.73 9 1.7 (0.8–3.2)
Acute leukemia 36 1.3 (0.9–1.8) 1 0.7 (0.0–4.1) 0 0 0.53 1 1.4 (0.0–7.9)
Polycythaemia vera 56 1.1 (0.8–1.4) 3 1.2 (0.2–3.4) 0 0 0.64 0 (0.8–1.4)
Unknown primary 467 1.1 (1.0–1.2) 27 1.3 (0.9–1.9) 3 1.1 (0.2–3.1) 0 0.95 12 1.1 (0.6–1.9)
Abbreviations: CI, confidence interval; FDR, first-degree relative; NC, not calculable.
Only tumor sites shown in Table 1 are presented, but sex-specific tumors (e.g., prostate tumor) from Table 1 are not repeated in Table 2; bold type: 95% CI did
not include 1.00; P-trend was calculated by the w2 test; FDR includes parents, siblings, and children.
1Example: The risk of squamous cell skin tumor was 1.4-fold elevated in male squamous cell skin tumor patients whose one FDR had a single melanoma,
compared with those whose FDRs had no melanoma, while the risk of squamous cell skin tumor was 2.0-fold elevated in male squamous cell skin tumor
patients whose X2 FDRs had a single melanoma, compared with those whose FDRs had no melanoma.
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studies have previously considered a detailed family history of
melanoma (increasing number of melanomas in 1 FDR or in
X2 FDRs) and the use of internal validation to assess familial
associations of melanoma with other tumors. We established
associations for 12 other tumors and also noted that the
associations for myeloid leukemia, parathyroid, and unknown
primary tumors have not been reported before. Our findings
suggest that, in addition to the contributions of shared
CDKN2A mutations for the cluster of melanoma with pan-
creatic, lung, and breast tumors, other shared and perhaps
unknown susceptibility genes may contribute to the reported
clustering. Shared UVR damage may link melanoma and
squamous cell skin tumors, whereas UVR-induced immuno-
suppression may predispose to mycosis fungoides and myeloid
leukemia. A better understanding of familial associations of
melanoma with other tumors should expand our etiological
understanding of cancer and may provide opportunities for
prevention through risk avoidance, counseling, and mutation
testing and screening.
MATERIALS AND METHODS
The FCD was created in the 1990s by linking information from the
Multigeneration Register, national censuses, Swedish Cancer Registry,
and death notifications, using an individually unique national
registration number (Hemminki et al., 2001a). For the latest version
of the FCD (FCD2010, updated in 2013), the Multigeneration Register
was linked to the Swedish Cancer Registry for the years 1958–2010.
Cancer cases were retrieved from the Swedish Cancer Registry,
relying on separate compulsory notifications from clinicians, pathol-
ogists, and cytologists, and close to 100% of the registered neoplasms
were histologically verified (Hemminki et al., 2001a). As basal cell
carcinoma of the skin is not registered in Sweden, only squamous cell
skin tumors were reported in this study. Tumors were recorded
according to the International Classification of Diseases, Seventh
Table 3. Standardized incidence ratios (SIRs) of other tumors in female patients with a detailed family history of
melanoma in Sweden, 1958–20101
Number of melanomas in one FDR Single melanoma
1 2 3 X4 in X2 FDRs
Tumor sites N SIR 95% CI N SIR 95% CI N SIR 95% CI N SIR 95% CI P-trend N SIR 95% CI
Pancreas 390 1.1 (1.0–1.2) 29 1.6 (1.1–2.3) 6 2.3 (0.9–5.1) 3 3.7 (0.8–10.8) 0.06 21 2.1 (1.3–3.2)
Lung 813 1.0 (0.9–1.0) 55 1.4 (1.0–1.8) 7 1.3 (0.5–2.7) 2 1.1 (0.1–3.8) 0.16 38 1.5 (1.1–2.1)
Skin (squamous cell) 1,792 1.4 (1.3–1.5) 113 1.8 (1.5–2.1) 15 1.7 (1.0–2.9) 4 1.4 (0.4–3.5) 0.18 88 2.4 (2.0–3.0)
Eye 69 1.4 (1.1–1.8) 4 1.7 (0.5–4.4) 0 0 0.82 4 3.0 (0.8–7.8)
Nervous system 729 1.3 (1.2–1.3) 34 1.2 (0.8–1.7) 3 0.7 (0.2–2.2) 4 3.0 (0.8–7.7) 0.74 19 1.1 (0.7–1.8)
Glioma 257 1.3 (1.1–1.4) 13 1.3 (0.7–2.2) 2 1.4 (0.2–5.2) 0 0.97 7 1.2 (0.5–2.5)
Ependymoma 17 1.4 (0.8–2.3) 2 3.4 (0.4–12.2) 0 0 0.56 1 3.0 (0.1–16.6)
Meningioma 300 1.3 (1.2–1.5) 12 1.1 (0.6–1.9) 1 0.6 (0.0–3.6) 3 6.0 (1.2–17.6) 0.77 5 0.7 (0.2–1.7)
Thyroid glands 266 1.2 (1.0–1.3) 9 0.8 (0.4–1.5) 2 1.2 (0.1–4.5) 0 0.86 6 0.9 (0.3–2.0)
Endocrine glands 396 1.0 (0.9–1.2) 24 1.3 (0.8–1.9) 7 2.7 (1.1–5.6) 2 2.4 (0.3–8.5) 0.09 18 1.7 (1.0–2.6)
Parathyroid glands 293 1.1 (1.0–1.2) 21 1.6 (1.0–2.4) 6 3.2 (1.2–7.0) 2 3.3 (0.4–11.9) 0.07 13 1.7 (0.9–2.9)
Pituitary glands 49 1.0 (0.7–1.3) 3 1.2 (0.2–3.5) 1 2.8 (0.1–15.4) 0 0.60 3 2.0 (0.4–5.8)
Bone 40 1.1 (0.8–1.4) 6 3.2 (1.2–7.0) 0 0 0.20 0
Osteosarcoma 9 1.0 (0.5–1.9) 4 9.2 (2.5–23.6) 0 0 0.13 0 (0.7–2.4)
Connective tissue 147 1.3 (1.1–1.5) 3 0.5 (0.1–1.6) 2 2.5 (0.3–9.1) 1 5.8 (0.1–32.1) 0.96 6 1.9 (0.7–4.1)
Non-Hodgkin lymphoma 467 1.1 (1.0–1.2) 20 0.9 (0.6–1.5) 2 0.7 (0.1–2.4) 1 1.0 (0.0–5.8) 0.47 16 1.3 (0.7–2.1)
Mycosis fungoides 3 0.4 (0.1–1.3) 0 0 0 NC 0
Leukemia 541 1.2 (1.1–1.3) 35 1.5 (1.1–2.1) 0 4 3.8 (1.0–9.7) 0.18 29 2.3 (1.5–3.2)
Myeloid leukemia 184 1.0 (0.9–1.2) 17 1.9 (1.1–3.0) 0 1 2.4 (0.1–13.5) 0.13 14 2.7 (1.5–4.6)
Acute leukemia 28 1.3 (0.8–1.8) 0 0 0 NC 1 1.7 (0.0–9.4)
Polycythaemia vera 70 1.4 (1.1–1.8) 4 1.6 (0.4–4.1) 0 1 8.9 (0.2–49.9) 0.53 4 2.9 (0.8–7.4)
Unknown primary 569 1.1 (1.0–1.2) 35 1.3 (0.9–1.9) 3 0.8 (0.2–2.4) 1 1.3 (0.0–7.2) 0.45 12 0.8 (0.4–1.4)
Abbreviations: CI, confidence interval; FDR, first-degree relative; NC, not calculable.
Only tumor sites shown in Table 1 are presented, but sex-specific tumors (e.g., ovarian tumor) from Table 1 are not repeated in Table 3; bold type: 95% CI did
not include 1.00; P-trend was calculated by the w2 test; FDR includes parents, siblings, and children.
1Example: The risk of leukemia was 1.2-fold elevated in female leukemia patients whose one FDR had single melanoma, compared with those whose FDRs
had no melanoma, while the risk of leukemia was 2.3-fold elevated in female leukemia patients whoseX2 FDRs had single melanoma, compared with those
whose FDRs had no melanoma.
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version (ICD-7), with separately recorded information on up to five
primary cancers and five carcinomas in situ. Four-digital ICD-7 codes
were used for subsites of nervous system and endocrine tumors, non-
Hodgkin’s lymphoma, and leukemia. Pathological anatomic
diagnosis codes were used for histological subtypes of nervous
system, bone, and eye tumors. The FCD2010 comprises over 14
million individuals and approximately 2 million patients with any
tumor (invasive cancers or carcinomas in situ), including the first and
multiple primaries.
Data on family relationships were obtained from the Multigenera-
tion Register with high-quality and practically complete coverage
(Hemminki et al., 2001a), thus minimizing bias related to the
reporting of family history, selection, and recall. Family history
information was obtained on all FDRs, including parents, siblings,
and children. A detailed family history of melanoma was investigated
according to the increasing number of melanomas (1, 2, 3, and X4
melanomas) in 1 FDR or X2 FDRs.
SIRs were calculated for other tumors (tumors other than mela-
noma) in patients who had a detailed family history of melanoma but
who did not have a melanoma diagnosis themselves, compared with
those who did not have either a personal or a family history of
melanoma. The expected case numbers were calculated from the
strata-specific other tumor incidence rate in patients with other
tumors who did not have a family history of melanoma, multiplied
by the corresponding person-years for patients with other tumors who
also had a family history of melanoma. The follow-up was started for
each individual at birth, immigration, or on 1 January 1958,
whichever came first. Follow-up was terminated on diagnosis of
other tumor, death, emigration, or the closing data of the study (31
December 2010), whichever came earliest. The present analyses
were restricted to individuals with at least one FDR, leading to over
12 million individuals and over 1.4 million patients with any tumor.
There were 248,011 individuals with a family history of melanoma (at
least 1 FDR had X1 melanomas) from 1958 to 2010. Among them,
43,931 had other tumors (in total).
All SIRs were adjusted for age (5-year bands), sex, calendar year at
diagnosis of the first tumor (10 groups), a four-category residential
area (large cities, South Sweden, North Sweden, or unspecified), and
a six-category socioeconomic level (farmer, manual workers, low- to
middle-income office worker, high-income office worker/profes-
sional, company owner (except farmer), or other/unspecified). The
95% confidence intervals for SIRs were calculated by assuming that
the cases followed a Poisson distribution. In addition to overall
analyses, sex-specific analyses on SIRs were also conducted. The Chi-
square test was used to assess linear trends in SIRs by the increasing
number of melanomas in 1 FDR or X2 FDRs as the Chi-square test
was applied by similar studies for assessing linear trends in SIRs
(Hjalgrim et al., 2000; Signorello et al., 2001). SAS software (version
9.3, SAS Institute, Cary, NC) was used for the data analyses. The Lund
regional Ethics Committee in Sweden approved the study.
In order to avoid chance findings, we set up rules for showing the
results in the Tables and for calling an association significant. Table 1
presents the results of overall analyses, showing only tumor sites with
at least a significant SIR in either 1 FDR orX2 FDRs (if one subtype of
a tumor site had a significant SIR, then the main site is also presented).
Tables 2 and 3 present the results of sex-specific analyses, showing
only tumor sites presented in Table 1, but sex-specific tumors (e.g.,
prostate cancer) from Table 1 are not repeated in Tables 2 and 3. In
this study, we considered an association ‘‘significant’’ only when
there were at least two independently significant SIRs or a statistically
significant trend of increasing SIRs with an increasing number of
melanomas in 1 FDR or in X2 FDRs.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We appreciate statistical consulting from Christoph Frank (Division of
Molecular Genetic Epidemiology, German Cancer Research Center) and
Xiaoqi Jiang (Division of Biostatistics, German Cancer Research Center). This
work was supported by the Swedish Research Council, the ALF project grants
(Lund, Sweden), the Swedish Council for Working Life, and the German
Cancer Aid (Deutsche Krebshilfe). The study sponsors were not involved in the
study design, data collection, data analysis, interpretation of results, writing of
the manuscript, and in the decision to submit the manuscript for publication.
REFERENCES
Amundadottir LT, Thorvaldsson S, Gudbjartsson DF et al. (2004) Cancer as a
complex phenotype: pattern of cancer distribution within and beyond the
nuclear family. PLoS Med 1:e65
Azizi E, Friedman J, Pavlotsky F et al. (1995) Familial cutaneous malignant
melanoma and tumors of the nervous system. A hereditary cancer
syndrome. Cancer 76:1571–8
Bermejo JL, Hemminki K (2005) Familial risk of cancer shortly after diagnosis
of the first familial tumor. J Natl Cancer Inst 97:1575–9
Borg A, Sandberg T, Nilsson K et al. (2000) High frequency of multiple
melanomas and breast and pancreas carcinomas in CDKN2A mutation-
positive melanoma families. J Natl Cancer Inst 92:1260–6
Brandt A, Sundquist J, Hemminki K (2011) Risk of incident and fatal melanoma
in individuals with a family history of incident or fatal melanoma or any
cancer. Br J Dermatol 165:342–8
Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation
carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:
1310–6
Bubien V, Bonnet F, Brouste V et al. (2013) High cumulative risks of cancer in
patients with PTEN hamartoma tumour syndrome. J Med Genet 50:
255–63
Cooper KD, Oberhelman L, Hamilton TA et al. (1992) UV exposure reduces
immunization rates and promotes tolerance to epicutaneous antigens in
humans: relationship to dose, CD1a-DRþ epidermal macrophage induc-
tion, and Langerhans cell depletion. Proc Natl Acad Sci USA 89:
8497–501
Czajkowski R, Placek W, Drewa G et al. (2004) FAMMM syndrome:
pathogenesis and management. Dermatol Surg 30:291–6
Evans AV, Scarisbrick JJ, Child FJ et al. (2004) Cutaneous malignant melanoma
in association with mycosis fungoides. J Am Acad Dermatol 50:701–5
Ford D, Easton DF, Stratton M et al. (1998) Genetic heterogeneity and
penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer
families. The Breast Cancer Linkage Consortium. Am J Hum Genet
62:676–89
Gale RP, Opelz G (2012) Commentary: does immune suppression increase risk
of developing acute myeloid leukemia? Leukemia 26:422–3
Goldstein AM, Tucker MA (2001) Genetic epidemiology of cutaneous
melanoma: a global perspective. Arch Dermatol 137:1493–6
Hemminki K, Li X, Plna K et al. (2001a) The nation-wide Swedish Family-
Cancer Database—updated structure and familial rates. Acta Oncol 40:
772–7
Hemminki K, Lonnstedt I, Vaittinen P (2001b) A population-based study of
familial cutaneous melanoma. Melanoma Res 11:133–40
Hemminki K, Sundquist J, Bermejo JL (2008) How common is familial cancer?
Ann Oncol 19:163–7
Hemminki K, Sundquist J, Brandt A (2012) Do discordant cancers share
familial susceptibility? Eur J Cancer 48:1200–7
T Chen et al.
Effect of Family History of Melanoma on Risk for Other Tumors
www.jidonline.org 935
Hjalgrim H, Askling J, Sorensen P et al. (2000) Risk of Hodgkin’s disease and
other cancers after infectious mononucleosis. J Natl Cancer Inst 92:
1522–8
Larson AA, Leachman SA, Eliason MJ et al. (2007) Population-based assess-
ment of non-melanoma cancer risk in relatives of cutaneous melanoma
probands. J Invest Dermatol 127:183–8
Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline
mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol
22:735–42
Lynch HT, Fusaro RM, Danes BS et al. (1983) A review of hereditary malignant
melanoma including biomarkers in familial atypical multiple mole
melanoma syndrome. Cancer Genet Cytogenet 8:325–58
Lynch HT, Fusaro RM, Lynch JF et al. (2008) Pancreatic cancer and the
FAMMM syndrome. Familial Cancer 7:103–12
Lynch HT, Fusaro RM, Pester J et al. (1981) Tumour spectrum in the FAMMM
syndrome. Br J Cancer 44:553–60
Mason RS, Reichrath J (2013) Sunlight vitamin d and skin cancer. Anti-Cancer
Agents Med Chem 13:83–97
Narayanan DL, Saladi RN, Fox JL (2010) Ultraviolet radiation and skin cancer.
Int J Dermatol 49:978–86
Pielop JA, Brownell I, Duvic M (2003) Mycosis fungoides associated with
malignant melanoma and dysplastic nevus syndrome. Int J Dermatol
42:116–22
Puig S, Ruiz A, Castel T et al. (1997) Inherited susceptibility to several cancers
but absence of linkage between dysplastic nevus syndrome and CDKN2A
in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
Hum Genet 101:359–64
Rulyak SJ, Brentnall TA, Lynch HT et al. (2003) Characterization of the
neoplastic phenotype in the familial atypical multiple-mole melanoma-
pancreatic carcinoma syndrome. Cancer 98:798–804
Shah M, Zhu K, Palmer RC et al. (2007) Family history of cancer and utilization
of prostate, colorectal and skin cancer screening tests in U.S. men. Prev
Med 44:459–64
Signorello LB, Ye W, Fryzek JP et al. (2001) Nationwide study of cancer risk
among hip replacement patients in Sweden. J Natl Cancer Inst 93:1405–10
Stacey SN, Sulem P, Masson G et al. (2009) New common variants affecting
susceptibility to basal cell carcinoma. Nat Genet 41:909–14
Ullrich SE (2005) Mechanisms underlying UV-induced immune suppression.
Mutat Res 571:185–205
Wiesner T, Fried I, Ulz P et al. (2012) Toward an improved definition of the
tumor spectrum associated with BAP1 germline mutations. J Clin Oncol
30:e337–40
T Chen et al.
Effect of Family History of Melanoma on Risk for Other Tumors
936 Journal of Investigative Dermatology (2014), Volume 134
